Kymera Therapeutics首位患者在Broaden2 II期B临床试验中接受KT-621治疗,这是一种首创的口服Stat6降解剂

美股速递
Nov 25, 2025

Kymera Therapeutics首位患者在Broaden2 II期B特应性皮炎临床试验中接受KT-621治疗,这是一种首创的口服Stat6降解剂

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10